Evidence map›Paper›PMID 28052018›Full record

ReviewOncotarget2017

Targeting microRNAs: a new action mechanism of natural compounds.

Qian Lin, Leina Ma, Zhantao Liu, Zhihong Yang, Jin Wang, Jia Liu, Guohui Jiang

Open access · diamondAbstract readReview
In one paragraph

Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Zygo-Albuside A: New Saponin fromInternational journal of molecular sciences · 2022
    Article
  9. Plants (Basel, Switzerland) · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Nobiletin Inhibits Non-Small-Cell Lung Cancer by Inactivating WNT/Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Qian LinCollege of Medicine, Qingdao University, Qingdao, China.
Leina MaThe Department of Oncology, The First Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Zhantao LiuCollege of Medicine, Qingdao University, Qingdao, China.
Zhihong YangCollege of Medicine, Qingdao University, Qingdao, China.
Jin WangCollege of Medicine, Qingdao University, Qingdao, China.
Jia LiuCollege of Medicine, Qingdao University, Qingdao, China.
Guohui JiangCollege of Medicine, Qingdao University, Qingdao, China.
Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlike genetics, epigenetics involves the modification of genome without changes in DNA sequences, including DNA methylation, histone modification, chromatin remodeling and noncoding RNA regulation. MicroRNA (miRNA), a member of noncoding RNAs superfamily, participates in RNA interference through a unique mechanism. Currently, microRNAs have been found to be regulated by some natural compounds. Through altering the expression of miRNAs and influencing the downstream signaling pathways or target genes, several natural compounds exhibit its bioactivity in the prevention, diagnosis, therapy, prognosis and drug resistance of human diseases, such as cancer. In this review, several natural compounds and their studies about miRNA-related action mechanism were summarized. These studies provide a new insight into action mechanism by which natural compound exerts its bioactivity and a novel treatment strategy, demonstrating natural compound a promising remedy for clinical treatments.

Indexed as

Biological ProductsEpigenomicsHumansMicroRNAsBiological ProductsMicroRNAscancermiRNAsnatural compounds

Identifiers

PMID28052018
PMCPMC5362538
OpenAlexW2562403672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.